HomeCompareSYMQY vs CHD

SYMQY vs CHD: Dividend Comparison 2026

SYMQY yields 358.49% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYMQY wins by $5189.31M in total portfolio value
10 years
SYMQY
SYMQY
● Live price
358.49%
Share price
$0.56
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5189.33M
Annual income
$3,350,688,442.05
Full SYMQY calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — SYMQY vs CHD

📍 SYMQY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYMQYCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYMQY + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYMQY pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYMQY
Annual income on $10K today (after 15% tax)
$30,471.41/yr
After 10yr DRIP, annual income (after tax)
$2,848,085,175.74/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, SYMQY beats the other by $2,848,084,077.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYMQY + CHD for your $10,000?

SYMQY: 50%CHD: 50%
100% CHD50/50100% SYMQY
Portfolio after 10yr
$2594.68M
Annual income
$1,675,344,867.27/yr
Blended yield
64.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

SYMQY
No analyst data
Altman Z
-15.4
Piotroski
2/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYMQY buys
0
CHD buys
0
No recent congressional trades found for SYMQY or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYMQYCHD
Forward yield358.49%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$5189.33M$26.4K
Annual income after 10y$3,350,688,442.05$1,292.51
Total dividends collected$5014.82M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SYMQY vs CHD ($10,000, DRIP)

YearSYMQY PortfolioSYMQY Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$46,549$35,848.72$10,856$156.32+$35.7KSYMQY
2$205,762$155,954.38$11,811$195.24+$194.0KSYMQY
3$864,438$644,273.43$12,883$244.38+$851.6KSYMQY
4$3,454,575$2,529,625.76$14,091$306.64+$3.44MSYMQY
5$13,144,248$9,447,852.61$15,463$385.88+$13.13MSYMQY
6$47,660,569$33,596,224.50$17,033$487.17+$47.64MSYMQY
7$164,846,065$113,849,255.31$18,843$617.36+$164.83MSYMQY
8$544,400,504$368,015,214.66$20,947$785.72+$544.38MSYMQY
9$1,718,361,020$1,135,852,481.39$23,419$1,004.91+$1718.34MSYMQY
10$5,189,334,734$3,350,688,442.05$26,350$1,292.51+$5189.31MSYMQY

SYMQY vs CHD: Complete Analysis 2026

SYMQYStock

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

Full SYMQY Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this SYMQY vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYMQY vs SCHDSYMQY vs JEPISYMQY vs OSYMQY vs KOSYMQY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.